/images/ppid_59c68470-image-178029761994544195.webp)
What is the story about?
Shares of Wockhardt
Ltd. surged over 19% on Monday, June 1, after the company became the first Indian drugmaker to secure US Food and Drug Administration (USFDA) approval for a novel antibiotic discovered and developed in India.
The USFDA approved Wockhardt's antibiotic WCK 5222, marketed under the brand name Zaynich, for the treatment of complicated urinary tract infections (cUTIs).
The intravenous antibiotic is designed for hospital use and targets multidrug-resistant bacterial infections, commonly referred to as "superbugs", an area of growing concern for global healthcare systems.
The approval marks a major milestone for India's pharmaceutical industry, as Zaynich is the country's first indigenously discovered antibiotic to receive regulatory clearance in the United States.
Zaynich had earlier received both Fast Track and Qualified Infectious Disease Product (QIDP) designations from the USFDA, enabling an accelerated review process.
Wockhardt filed its New Drug Application (NDA) for the drug in October 2025 and secured approval in less than a year.
The drug also received approval from India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), on May 28 following positive Phase 3 trial results, where it outperformed the widely used antibiotic meropenem.
In Europe, the drug was granted Accelerated Assessment status in December 2025, potentially paving the way for a faster regulatory review.
Industry estimates peg the global market for treatments targeting multidrug-resistant infections at nearly $9 billion.
Analysts believe Zaynich could eventually generate annual sales of $1 billion to $2 billion worldwide, with the US market accounting for nearly 40% of the revenue opportunity.
In India, the antibiotic is expected to generate around ₹150 crore in sales during its initial one to two years following launch.
The drug's development involved more than a decade of research, clinical trials and regulatory work. Wockhardt also said that 85 critically ill patients have already received treatment under its compassionate-use programme.
Investors will now watch for potential global licensing agreements and distribution partnerships that could accelerate commercialisation across international markets.
Beyond Zaynich, Wockhardt continues to strengthen its anti-infective portfolio. Its pipeline includes MIQNAF, which has already been launched in India, while Emrok and Emrok O reported 106% year-on-year growth during the March quarter.
The company has also completed Phase 4 trials for FOVISCU in India.
The USFDA approved Wockhardt's antibiotic WCK 5222, marketed under the brand name Zaynich, for the treatment of complicated urinary tract infections (cUTIs).
The intravenous antibiotic is designed for hospital use and targets multidrug-resistant bacterial infections, commonly referred to as "superbugs", an area of growing concern for global healthcare systems.
The approval marks a major milestone for India's pharmaceutical industry, as Zaynich is the country's first indigenously discovered antibiotic to receive regulatory clearance in the United States.
Zaynich had earlier received both Fast Track and Qualified Infectious Disease Product (QIDP) designations from the USFDA, enabling an accelerated review process.
Wockhardt filed its New Drug Application (NDA) for the drug in October 2025 and secured approval in less than a year.
The drug also received approval from India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), on May 28 following positive Phase 3 trial results, where it outperformed the widely used antibiotic meropenem.
In Europe, the drug was granted Accelerated Assessment status in December 2025, potentially paving the way for a faster regulatory review.
Industry estimates peg the global market for treatments targeting multidrug-resistant infections at nearly $9 billion.
Analysts believe Zaynich could eventually generate annual sales of $1 billion to $2 billion worldwide, with the US market accounting for nearly 40% of the revenue opportunity.
In India, the antibiotic is expected to generate around ₹150 crore in sales during its initial one to two years following launch.
The drug's development involved more than a decade of research, clinical trials and regulatory work. Wockhardt also said that 85 critically ill patients have already received treatment under its compassionate-use programme.
Investors will now watch for potential global licensing agreements and distribution partnerships that could accelerate commercialisation across international markets.
Beyond Zaynich, Wockhardt continues to strengthen its anti-infective portfolio. Its pipeline includes MIQNAF, which has already been launched in India, while Emrok and Emrok O reported 106% year-on-year growth during the March quarter.
The company has also completed Phase 4 trials for FOVISCU in India.
/images/ppid_59c68470-image-17801400362887646.webp)
/images/ppid_a911dc6a-image-178019403897857906.webp)
/images/ppid_59c68470-image-17802775305757585.webp)
/images/ppid_59c68470-image-178004008927449014.webp)
/images/ppid_59c68470-image-178003002438094569.webp)
/images/ppid_59c68470-image-178003504027437744.webp)
/images/ppid_59c68470-image-178006508859373916.webp)